Evidence map›Paper›PMID 30013936›Full record

ArticleJournal of clinical & translational endocrinology2018

Influence of peroxisome proliferator-activated receptor-γ exon 2 and exon 6 and insulin receptor substrate (IRS)-1 Gly972Arg polymorphisms on insulin resistance and beta-cell function in southern mediterranean women with polycystic ovary syndrome.

Annalisa Giandalia, Maria Angela Pappalardo, Giuseppina T Russo, Elisabetta L Romeo, Angela Alibrandi, Flavia Di Bari, Roberto Vita, Domenico Cucinotta, Salvatore Benvenga

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Polycystic Ovarian Syndrome: A Review of Multi-omics Analyses.Reproductive sciences (Thousand Oaks, Calif.) · 2025
    Review
  2. Experimental and therapeutic medicine · 2023
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Annalisa GiandaliaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Maria Angela PappalardoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Giuseppina T RussoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Elisabetta L RomeoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Angela AlibrandiDepartment of Economics, University of Messina, Viale Gazzi, 98125 Messina, Italy.
Flavia Di BariDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Roberto VitaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Domenico CucinottaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Salvatore BenvengaDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
University of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe Pro12Ala (exon 2) and His447His (exon 6) polymorphisms of PPAR-γ, and Gly972Arg polymorphism of IRS-1 have been implicated in insulin resistance (IR) and adiposity. Our aim was to investigate the influence of these polymorphisms on metabolic features of polycystic ovary syndrome (PCOS).

methodsFifty-three PCOS women and 26 control women underwent a clinical and biochemical evaluation, including a 75-g oral glucose tolerance test. Insulin secretion and insulin sensitivity indices were calculated.

resultsFrequencies of PPAR-γ polymorphisms did not differ from those predicted by the Hardy-Weinberg equilibrium. Instead, the IRS-1 Gly972Arg allele was significantly more frequent in the PCOS group compared to controls. The most frequent allelic combinations were IRS1+/exon2-/exon6- (which prevailed in PCOS) and IRS-1-/exon2-/exon6- (which prevailed in controls). Among PCOS women, compared with the wild type patients, carriers of the Gly972Arg IRS-1 allele had lower E2 levels, while carriers of the Pro12Ala PPAR-γ (exon 2) allele had lower free testosterone levels. No other significant relationships were noted. When compared with the wild type, in PCOS group IR and beta-cell function were: (i) trendwise greater in carriers of the variant IRS-1 allele; (ii) trendwise lower in carriers of the variant PPAR-γ exon 6 allele; (iii) significantly lower in carriers of the variant PPAR-γ exon 2 allele.

conclusionsOur data support the protective influence of PPAR-γ-exon 2 and exon 6 variants on IR and beta cell function, whereas IRS-1 polymorphism is associated with an unfavorable metabolic profile. However, these associations do not fully explain the high metabolic risk associated with PCOS.

Indexed as

17-OHP, 17-hydroxyprogesteroneAE-PCOS, Androgen Excess and Polycystic Ovary Syndrome SocietyBMI, body mass indexDI, disposition indexE2, 17β-estradiolFSH, follicular stimulating hormoneHDL, high-density lipoproteinHOMA-IR, homeostasis model assessmentIGI, insulinogenic indexInsulin receptor substrate-1IRS, insulin receptor substrateLDL, low-density lipoproteinLH, luteinizing hormoneOGTT, oral glucose tolerance testPCOS, polycystic ovary syndromePCR, polymerase chain reactionPeroxisome proliferator-activated-receptor-gammaPolycystic ovary syndromePolymorphismsPPAR-γ, peroxisome proliferator activated receptor-γSHBG, sex hormone binding globulin

Identifiers

PMID30013936
PMCPMC6022250
OpenAlexW2804145385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.